COST-EFFECTIVENESS OF EICOSAPENTAENOIC ACID (EPA) ON PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
Author(s)
Kodera S, Kiyosue A, Ando J, Komuro I
University of Tokyo, tokyo, Japan
OBJECTIVES: Eicosapentaenoic acid (EPA) was shown to reduce cardiovascular events when added to statin therapy. The aim of this study is to analyze cost-effectiveness of EPA plus statin compared with statin monotherapy for primary prevention of cardiovascular disease in Japan. METHODS: Markov model was applied to assess the costs and benefits associated with EPA over a 30-year time horizon from Japanese health-care payer perspective. Incremental cost-effectiveness ratio (ICER) with benefits expressed as quality adjusted life year (QALY) was estimated. The impact on survival, number of events was based on the Japan EPA Lipid Intervention Study (JELIS). Sensitivity analyses were conducted to explore the influence of various input parameters on costs and outcomes. RESULTS: EPA-plus-statin therapy compared with statin monotherapy resulted in greater cost (total 30-year costs €31,899 vs €20,137 per person, respectively) and improved utilities (average 18.8 vs 18.7 QLAYs, respectively). ICER was €236,538 per QALY gained. At a cost-effectiveness threshold of €40,000 per QALY gained, the probability that EPA-plus-statin was cost-effective compared statin monotherapy was 39%. Sensitivity analyses showed much lower EPA drug cost might improve ICER within cost-effectiveness threshold. CONCLUSIONS: EPA plus statin was not cost-effective for primary prevention of cardiovascular disease in Japan.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCV78
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders